Recognition of a Litigation Settlement Payment by a U.S. Subsidiary
First written in FY2020-Q2. 5 of 9 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2019: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Other".
- FY2026Full-year settlement-related payments totaled ¥1,238 millionAnnual report
「Net cash provided by operating activities was ¥205 million, compared with ¥1,046 million in the previous consolidated fiscal year. The main source of cash was depreciation and amortization of ¥1,613 million, while the main uses of cash included a ¥1,537 million increase in inventories and ¥1,238 million in settlement-related payments.」
For the settlement-related expenses incurred in FY2025, a payment of ¥1,238 million was recorded in cash flow from operating activities in FY2026. - FY2026-H1Recognition of settlement-related paymentsAnnual report
「The main uses of cash were a ¥1,143 million increase in inventories and ¥1,201 million in settlement-related payments. The main source of cash was a ¥1,146 million decrease in trade receivables.」
Operating cash flow included a reported payment of ¥1,201 million in settlement-related expenses. - FY2024RestatedAnnual report
「¥75 million in settlement-related expenses incurred in the first quarter, among other items totaling ¥206 million, was recorded as an extraordinary loss.」
The ¥75 million in settlement-related expenses recorded in the first quarter was included in full-year extraordinary losses. - FY2024-Q3RestatedAnnual report
「Extraordinary items included ¥29 million in losses on disposal of medical instruments and other fixed assets and ¥75 million in settlement-related expenses incurred in the first quarter, totaling ¥104 million recorded as an extraordinary loss.」
The ¥75 million in settlement-related expenses recorded in the first quarter continued to be reported as an extraordinary loss for the nine-month period. - FY2024-Q2RestatedAnnual report
「Extraordinary items included ¥18 million in losses on disposal of medical instruments and other fixed assets and ¥75 million in settlement-related expenses incurred in the first quarter, totaling ¥93 million recorded as an extraordinary loss.」
The ¥75 million in settlement-related expenses recorded in the first quarter was again reported as an extraordinary loss for the six-month period. - FY2024-Q1Recognition of ¥75 million in settlement-related expensesAnnual report
「Extraordinary items included ¥9 million in losses on disposal of medical instruments and other fixed assets and ¥75 million in settlement-related expenses, totaling ¥84 million recorded as an extraordinary loss.」
¥75 million in settlement-related expenses was recorded as an extraordinary loss. The text does not expressly state whether this expense is the same as the ¥33 million litigation settlement payment by the U.S. subsidiary reported previously. The provision for litigation settlements fell from ¥100 million at the end of the previous consolidated fiscal year to zero at the end of the quarter under review. - FY2020RestatedAnnual report
「A ¥33 million litigation settlement payment by a U.S. subsidiary was recorded as an extraordinary loss.」
Recognition of the ¥33 million litigation settlement payment by a U.S. subsidiary was also confirmed for the full year. - FY2020-Q3RestatedAnnual report
「A ¥33 million litigation settlement payment by a U.S. subsidiary was recorded as an extraordinary loss.」
Recognition of the ¥33 million litigation settlement payment by a U.S. subsidiary continued to be reported for the nine-month period. - FY2020-Q2First statedAnnual report
「A ¥33 million litigation settlement payment by a U.S. subsidiary was recorded as an extraordinary loss.」
The ¥33 million litigation settlement payment by a U.S. subsidiary was reported as an extraordinary loss for the first time.